ABVX is one of three companies open in full. Every company in our coverage universe has a thesis like this one.
Sign up freeUpdated 67d ago
Abivax is a clinical-stage company developing an investigational targeted inflammatory drug for ulcerative colitis that is not yet approved, with Phase 3 efficacy data in hand but regulatory clearance hinging on the FDA's assessment of a potential safety signal.
Abivax built obefazimod around ulcerative colitis, an inflammatory bowel disease where existing therapies leave many patients inadequately treated, and its Phase 3 ABTECT program met primary endpoints at both induction and maintenance with a clean secondary endpoint sweep. The single binary is whether FDA accepts the expanded safety database, showing malignancy rates consistent with UC background, as sufficient to approve the 50 mg dose without a boxed warning or label restriction that would blunt commercial uptake. The $920M raise funds an independent U.S. launch, but a restrictive label or request for additional safety data would strand that capital against a diminished market opportunity.
Current Thesis Drivers
What could change the thesis?
Generated from public SEC filings and disclosures. For informational purposes only — not investment advice. Always conduct your own research before making investment decisions.
Abivax secured $920M in funding to pursue independent U.S. commercialization of obefazimod instead of partnering, strengthening its financial position for market entry.
Phase 3 maintenance data met all endpoints but a dose-dependent malignancy signal in the 50 mg arm triggered analyst downgrades and investor concern; the subsequent safety database update and $920M raise partially restored confidence, but FDA's evaluation of that cancer signal remains unresolved ahead of the NDA submission.
Source ↗Obefazimod met primary and all key secondary endpoints in Phase 3 ABTECT maintenance trial (39.3-40.3% clinical remission vs placebo) with favorable safety, supporting late Q4 2026 NDA submission for ulcerative colitis.
A dose-dependent solid tumor signal emerged in the 50 mg arm of the ABTECT maintenance trial (3 cases vs. 0 in placebo and 25 mg), creating material regulatory uncertainty for the planned NDA submission despite all efficacy endpoints being met.
Source ↗Abivax plans to submit a New Drug Application to the FDA for obefazimod in moderately to severely active ulcerative colitis in late Q4 2026, supported by the completed ABTECT Phase 3 maintenance dataset and expanded integrated safety database of 1,704 patient-years that resolved prior malignancy concerns.
The NDA submission is the pivotal value-creation milestone that transforms the $920M financing and Phase 3 success into a regulatory inflection point; the quality and completeness of the safety package—particularly the resolution of the June 2026 cancer signal overhang—will determine whether FDA accepts the filing and sets a review timeline. Investor attention is now concentrated on whether the integrated safety data is sufficient for a standard rather than restricted approval.
The expanded Phase 3 safety database demonstrates malignancy rates (0.35–0.64 per 100 patient-years) consistent with background UC population rates, supporting a clean benefit-risk narrative in the NDA; FDA accepts the submission with standard review and no additional safety studies required. With $920M in cash enabling a solo U.S. commercial launch, Abivax can build out its own sales infrastructure in parallel with FDA review, maximizing value retention from approval.
Despite the updated safety data, FDA could issue a Refusal to File or request additional carcinogenicity or long-term follow-up data given prior analyst and investor concern over malignancy signals, delaying the approval timeline materially beyond 2027. Execution risk on a solo U.S. commercial launch—without a large pharma partner's infrastructure—is high in a crowded UC market, and any new safety events emerging during the review period could reignite the cancer signal concern and compress peak sales estimates.
| Drug | Target | Dosing | Status |
|---|---|---|---|
obefazimod ABIVAX | miR-124 | oral · once daily | Phase 3 |
| Approved | |||
Tysabri2nd-line+ natalizumab · Biogen | anti-integrin antibody (alpha4-integrin) | IV · every four weeks | Approved |
Sotyktu (deucravacitinib) deucravacitinib · Bristol Myers Squibb | tyrosine kinase 2 inhibitor | oral · once daily | Approved |
Stelara (ustekinumab) ustekinumab · Johnson & Johnson | IL-12/23 inhibitor | IV · every 12 weeks | Approved |
Skyrizi (risankizumab) risankizumab · AbbVie | anti-IL-23 | SC · every 12 weeks | Approved |
Tremfya Johnson & Johnson | anti-IL-23 | SC · every 8 weeks | Approved |
mirikizumab Eli Lilly | anti-IL-23 | — | Approved |
Xeljanz (tofacitinib)post-TNF blocker tofacitinib · Pfizer | non-selective JAK inhibitor | oral · twice daily | Approved |
Jyseleca (filgotinib) filgotinib · Gilead/Galapagos/Alfasigma | selective JAK1 inhibitor | — | Approved |
Rinvoq (upadacitinib)post-TNF blocker upadacitinib · AbbVie | selective JAK1 inhibitor | oral · once daily | Approved |
Zeposia (ozanimod) ozanimod · BMS | S1P receptor modulator (S1P1 and S1P5) | oral · once daily | Approved |
Humira adalimumab · AbbVie | TNF-alpha | every other week | Approved |
Remicade2nd-line+ infliximab · Johnson & Johnson | TNFα | IV · every 8 weeks | Approved |
Entyvio vedolizumab · Takeda | α4β7 integrin | SC · every eight weeks thereafter or once every 2 weeks | Approved |
Omvoh mirikizumab-mrkz · Eli Lilly | IL-23 p19 subunit | SC · every 4 weeks | Approved |
| In development | |||
MORF-057 Morphic | anti-integrin | — | Pipeline |
PN-943 Protagonist/Johnson & Johnson | anti-integrin | — | Pipeline |
omilancor NImmune | Lanthionine Synthetase C-Like 2 activator | — | Pipeline |
VTX958 Ventyx | tyrosine kinase 2 inhibitor | — | Pipeline |